Article PDF
References
Vasudev NS, Larkin JM. Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib. Clin Med Insights Oncol 2011; 5: 333–42.
Welsh SJ, Fife K. Pazopanib for the treatment of renal cell carcinoma. Future Oncol 2015; 11: 1169–79.
Faye E, Bondon-Guitton E, Olivier-Abbal P, et al. Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors. Eur J Clin Pharmacol 2013; 69: 1819–26.
Sundriyal D, Kumar N. Pazopanib induced hand-foot syndrome. Oxf Med Case Reports 2015; 26: 206–7.
Fujita H, Oda K, Sato M, et al. Pazopanib-induced leg ulcer in a patient with malignant fibrous histiocytoma. J Dermatol 2014; 41: 1022–3.
Goto H, Niwakawa M, Yoshikawa S, et al. Case of severe ulceration induced by pazopanib. J Dermatol 2017; 44: 474–6.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Hioki, T., Takama, H., Makita, S. et al. Leg ulcers associated with cutaneous vascular degeneration in a patient receiving pazopanib chemotherapy. Eur J Dermatol 27, 546–547 (2017). https://doi.org/10.1684/ejd.2017.3092
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2017.3092